Celltrion Signs Supply Contract Worth 252.3 Billion KRW with Celltrion Healthcare
[Asia Economy Reporter Seongpil Cho] Celltrion announced on the 28th that it has signed a supply contract for biosimilar antibody drugs (Remsima IV, Herzuma, Remsima SC) with Celltrion Healthcare.
The contract amount is 252.3925 billion KRW, which corresponds to 22.36% of the sales in 2019.
Hot Picks Today
!["Rather Than Endure a 1.5 Million KRW Stipend, I'd Rather Earn 500 Million in the U.S." Top Talent from SNU and KAIST Are Leaving [Scientists Are Disappearing] ①](https://cwcontent.asiae.co.kr/asiaresize/93/2026051914165468840_1779167814.png)
"Rather Than Endure a 1.5 Million KRW Stipend, I'd Rather Earn 500 Million in the U.S." Top Talent from SNU and KAIST Are Leaving [Scientists Are Disappearing] ①
- "Not Jealous of Winning the Lottery"... Entire Village Stunned as 200 Million Won Jackpot of Wild Ginseng Cluster Discovered at Jirisan
- "I'll Stop by Starbucks Tomorrow": People Power Chungbuk Committee and Geoje Mayoral Candidate Face Criticism for Alleged 5·18 Demeaning Remarks
- "To Get Revenge on Ex-Girlfriend" US McDonald's Manager Spits on French Fries
- "How Did an Employee Who Loved Samsung End Up Like This?"... Past Video of Samsung Electronics Union Chairman Resurfaces
The contract period is until the 30th of this month.
This content was produced with the assistance of AI translation services.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
